Additional file 2 of Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues

Additional file 2: Table S1. Proteins significantly altered between post versus pre-NACT tissues (LIMMA p-value<0.01). Table S2. Proteins significantly altered between R1 versus R0 patients in pre-NACT tissues (LIMMA p-value<0.05). Table S3. Significantly (LIMMA p<0.05) co-altered proteins between pre-NACT tumors from patients with any level of residual disease vs R0 patients from an independent ovarian cancer cohort (CPTAC 2016) that exhibit highly correlated abundance trends with the present ovarian cancer cohort. Table S4. Diseases and biofunctions (Ingenuity Pathway Analysis) significantly enriched by proteins altered between R1 versus R0 patients in pre-NACT tissues (LIMMA p-value<0.05). Table S5. Proteins altered in R1 versus R0 patients in pre-NACT treated tumors significantly correlating with altered progression free survival in CPTAC ovarian 2016.